—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Tubize-Fin (TUB.BR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for TUB.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in Europe: −1.2% week · −3.2% month · −6.1% quarter · +2.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against TUB.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Tubize-Fin

TUB.BR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Tubize-Fin, formally Financière de Tubize, is a Brussels-based holding company whose main asset is a stake in UCB, a Belgian biopharmaceutical company working on treatments for immune and central-nervous-system disease. Tubize-Fin does not develop or sell drugs itself; its business is holding and managing that UCB position. The company traces back to 1928 and remains listed separately from UCB in Brussels.
Where it sits in the stack
Tubize-Fin carries no seat in Rubin, our index for the AI hardware build-out, and it sits outside that stack entirely. Within the diary's broader universe it falls into the Healthcare sleeve, as a holding vehicle for a stake in UCB rather than as a maker or supplier of anything in the AI chain.
Who it is priced against
The diary holds no peer group for Tubize-Fin. The comparison worth drawing is with UCB itself, the biopharmaceutical company whose shares it holds, since its own value tracks UCB's share price rather than any set of operating peers.
Why Closelooknet tracks it
Tubize-Fin carries a score in the diary, and momentum is the module the diary flags for it, with no other module data recorded. It holds no seat in Rubin or in our other indices, and it does not appear in any of our editions or quotes.
What the diary watches
The diary watches the gap between Tubize-Fin's own share price and the value of its UCB stake, since that gap, not any operating result, is what mainly moves the read on this name.

Tubize-Fin (TUB.BR) trades on the BR exchange in Belgium, classified under Healthcare.

The Closelooknet company score reads 25/100 composite (momentum 11, quality 20, valuation 27) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 0.45%, annual · last 0.76 EUR on 2026-05-07

Dividends and capital return

What TUB.BR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.76 EUR per share · a 0.45% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year +3.8% against the prior twelve months prior twelve months 0.73 EUR per share
  • Last distribution 0.76 EUR per share as the price series records it, within days of the ex-date 2026-05-07
  • By calendar year 2025: 0.73 EUR (partial) · 2026: 0.76 EUR to date first distribution recorded in the three-year window: 2025-04-30
  • Dividends paid, FY2025 46 m EUR 49% of earnings
  • Share count 0.0% in FY2025
  • Capital returned 46 m EUR · 50% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Tubize-Fin (TUB.BR)?

Tubize-Fin trades as TUB.BR on the BR exchange (Belgium) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is TUB.BR in a Closelooknet index?

Not currently — Tubize-Fin is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Tubize-Fin's Closelooknet composite score?

25 out of 100, with momentum 11, quality 20 and valuation 27 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does TUB.BR trade against its moving averages?

Downtrend stack: Trades -7.5% vs the 50-day and -18.8% vs the 200-day average, 32% below the 52-week high and +1% off the 52-week low; a death cross printed 42 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Tubize-Fin compare with its peers?

Against its peer group (Biotechnology), Tubize-Fin (TUB.BR) sits 32.0% below its 52-week high, 7.5% below its 50-day average; BB Biotech AG (BION.SW) is 12.9% below, BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below. Put any of them next to TUB.BR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Tubize-Fin do?

Tubize-Fin, formally Financière de Tubize, is a Brussels-based holding company whose main asset is a stake in UCB, a Belgian biopharmaceutical company working on treatments for immune and central-nervous-system disease. Tubize-Fin does not develop or sell drugs itself; its business is holding and managing that UCB position. The company traces back to 1928 and remains listed separately from UCB in Brussels. The diary holds no peer group for Tubize-Fin. The comparison worth drawing is with UCB itself, the biopharmaceutical company whose shares it holds, since its own value tracks UCB's share price rather than any set of operating peers.

Where does Tubize-Fin sit in the AI build-out?

Tubize-Fin carries no seat in Rubin, our index for the AI hardware build-out, and it sits outside that stack entirely. Within the diary's broader universe it falls into the Healthcare sleeve, as a holding vehicle for a stake in UCB rather than as a maker or supplier of anything in the AI chain. Tubize-Fin carries a score in the diary, and momentum is the module the diary flags for it, with no other module data recorded. It holds no seat in Rubin or in our other indices, and it does not appear in any of our editions or quotes.

Does Tubize-Fin pay a dividend?

Tubize-Fin has paid 0.76 EUR per share over the last twelve months, paid once a year, a trailing yield of 0.45% on the 2026-10-06 close; the last distribution recorded in the price series was 0.76 EUR on 2026-05-07. In fiscal 2025 the company paid 46 m EUR in dividends, 50% of that year’s free cash flow. The share count was unchanged over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TUB.BR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.